US- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer.
Philippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as COO in future.
Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.
Eduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV.
Uwe Meya is taking over as Chief Medical Officer at Barcelona-based orphan drug developer Minoryx Therapeutics. Meya will advance the clinical development of Minoryx’ lead candidate MIN-102 for adrenoleukodystrophy.
In July, British research service provider Envigo appointed Adrian Hardy as President and CEO. Hardy will also join Envigo’s Board of Directors.
US-Dutch medical device company EndoStim, developer of neurostimulation therapy for gastroesophageal reflux disease, has named Rohan Hoare as president and CEO. He succeeds founder Bevil Hogg, who will continue to serve the company as a consultant.
Antibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the company’s helm for good. Kymab’s new old CEO is stepping down from his role as Chairman, however.
The EMA’s Committee for Medicinal Products for Veterinary Use (CVMP) has unanimously appointed David Murphy from Ireland as its new Chair for the next three years. Murphy, a qualified veterinarian, is the Veterinary Assessment Manager at the Health Products Regulatory Authority in Ireland.
Torsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy Officer.